Matt reckons that BOT's product will be commercially available from 2021:

from:
https://www.sbs.com.au/news/the-feed/cannabidiol-manufacturer-claims-the-cannabis-derivative-has-no-real-side-effects

CBD BUSINESS IN AUSTRALIA

ASX-listed companyBotanix Pharmaceuticalsis currently conducting several clinical trials in Australia.

They’re trying to prove that CBD is an effective treatment for skin diseases like eczema and acne.

However, the CBD used in their trials isn’t derived from a cannabis plant - they’ve created a synthetic alternative.

“CBD is just a molecule, you can extract it from a plant but it won’t be very pure. The reason we use a synthetic is because we can get it 100% pure all the time,” Botanix executive director Matt Callahan toldThe Feed.

“Regulators don’t like drugs that have bits of other chemicals in them, just as you wouldn’t want any other drugs when you’re taking a Panadol.”

Callahan says that for pharmaceutical purposes, CBD products will most likely be made synthetically.

CBD is very easy to make and it’s more cost effective to make it rather than extract it from a plant.

One of Bontanix’s clinical trials is about to enter its third phase and Callahan is confident that their CBD products will be commercially available in Australia by 2021.

The US CBD market reached an estimated value of US$510 million in 2018. That number is predicted to jump to $22 billion in 2022.

Callahan envisions a future where Australia’s CBD market mirrors that in the US, with the potential value being “hundreds of millions”.
“I think it’s inevitable, it’s a chemical with no real side effects that are dangerous to humans and lots of potential benefits. At worst, it’s a functional food.”